Navigation Links
Mass. General-based research center will investigate why immune system fails to control hepatitis C
Date:7/22/2009

A research consortium based at Massachusetts General Hospital (MGH) has been awarded $15 million from the National Institute of Allergy and Infectious Diseases to investigate how the hepatitis C virus (HCV) resists suppression and clearance by the immune system. The five-year grant will support a Cooperative Center for Translational Research in Human Immunology, which also will focus on how some individuals successfully recover from HCV while the infection becomes chronic in most of those infected, with a special emphasis on immunological events in the liver as the site of HCV replication.

"Hepatitis C is a major global health problem for which existing therapies are inadequate," says Raymond Chung, MD, director of Hepatology in the MGH Gastrointestinal Unit and co-director of the research center. "Improving our understanding of how and why the virus consistently evades immune system control should lead us to better ways of treating hepatitis C and possibly other chronic viral infections." Chung will lead a project to better define the role of the liver cells called hepatocytes in the innate and adaptive immune response to HCV infection.

Center co-director Paul Klenerman, PhD, of Oxford University will examine properties of the T cells that migrate to the liver in response to HCV infection. Additional principal investigators and project goals are:

  • Georg Lauer, MD, PhD, MGH Gastrointestinal Unit, and John Wherry, PhD, Wistar Institute investigate the functional capacity of CD4 and CD8 T cells within the liver in chronic HCV infection;
  • Todd Allen, PhD, Ragon Institute of MGH, MIT and Harvard, and Matthew Henn, PhD, Broad Institute of MIT and Harvard examine how selection pressure applied by T cells affects HCV evolution;
  • Gordon Freeman, PhD, Dana-Farber Cancer Institute develop a panel of reagents designed to modulate signaling in key immune cells;
  • Joseph Misdraji, MD, MGH Pathology create a library of liver cells and tissue from HCV-infected and uninfected patients to use in study experiments;
  • Nicholas Haining, MB, ChB, Dana-Farber develop high-throughput technology platforms to examine and modulate signals inhibiting the immune response.

Almost 170 million people worldwide are infected with HCV, 50 to 80 percent of whom will develop chronic hepatitis, which can lead to cirrhosis, liver cancer or liver failure. Identifying the factors that allow HCV to survive in spite of the immune response against the virus may also improve understanding of immune system failure in other chronic infections, including HIV, Epstein-Barr virus, and tuberculosis.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform
2. Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies
3. Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study
4. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
5. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
6. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
7. Cryo-Cell Announces Celle(SM) Research and Development Collaboration for Chronic Wound Healing Management
8. Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
9. Major NIMH research project to test approaches to altering the course of schizophrenia
10. Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says
11. Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: